Silence Therapeutics plc Stock
Stocks
SLN
US82686Q1013
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq
16:00:00 2026-10-22 EDT
|
5-day change | 1st Jan Change | ||
| 19.66 USD | -0.05% |
|
+110.27% | +223.36% |
| 10-19 | Health Care Up on Deal Activity - Health Care Roundup | DJ |
| 10-19 | Silence Therapeutics to Be Acquired by Germany's Merck in $1.3 Billion Deal; Shares Surge | MT |
| Market Cap | 886M 1.18B 1.06B 975M 1.66B 112B 1.69B 11.75B 4.63B 58.77B 4.45B 4.35B 186B | P/E 2026 * |
-38.5x | P/E 2027 * | -31.7x |
|---|---|---|---|---|---|
| Enterprise Value | 752M 1B 897M 827M 1.41B 95.17B 1.43B 9.97B 3.93B 49.86B 3.77B 3.69B 158B | EV / Sales 2026 * |
2,286x | EV / Sales 2027 * | 934x |
| Free-Float |
69.35% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| SLN | Delayed | |
CBOE
| SLN | Real-time | |
|
Tradegate
| XRP2 | Real-time | |
|
Deutsche Boerse AG
| XRP2 | Delayed | |
|
Börse Stuttgart
| XRP2 | Delayed | |
|
Boerse Muenchen
| XRP2 | Real-time |
Last Transcript: Silence Therapeutics plc
| 1 day | -0.05% | ||
| 1 week | +110.27% | ||
| Current month | +79.87% | ||
| 1 month | +59.97% | ||
| 3 months | +66.19% | ||
| 6 months | +146.68% | ||
| Current year | +223.36% |
| 1 week | 19.56 |  | 19.69 |
| 1 month | 8.66 | | 19.69 |
| Current year | 4.19 | | 19.69 |
| 1 year | 4.19 | | 19.69 |
| 3 years | 1.97 | | 27.72 |
| 5 years | 1.97 | | 27.72 |
| 10 years | 1.97 | | 35 |
| Manager | Title | Age | Since |
|---|---|---|---|
Iain Ross
CEO | Chief Executive Officer | 72 | 2025-11-30 |
Rhonda Hellums
DFI | Director of Finance/CFO | 54 | 2022-01-31 |
Curtis Rambaran
CTO | Chief Tech/Sci/R&D Officer | - | 2020-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
David Lemus
BRD | Director/Board Member | 63 | 2018-06-20 |
Iain Ross
CHM | Chairman | 72 | 2003-12-31 |
Tim McInerney
BRD | Director/Board Member | 65 | 2025-05-04 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 7/6/26 | Sell | 865,112 | 0.6105% | |||
| 1/2/26 | Free | Chief Financial Officer | 375,000 | 0.2646% | ||
| 1/2/26 | Free | Director | 90,000 | 0.0635% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.05% | +110.27% | +173.06% | +175.74% | 1.18B | |
| -4.10% | -8.54% | +40.05% | +66.99% | 63.29B | |
| -0.54% | +7.09% | +10.59% | +72.81% | 54.89B | |
| -0.22% | +3.77% | +9.20% | +91.33% | 53.28B | |
| +0.61% | +2.69% | +27.75% | +50.97% | 45.81B | |
| -1.08% | +2.19% | +21.92% | +131.38% | 43.46B | |
| -3.39% | -0.83% | +254.27% | +571.04% | 40.23B | |
| -1.67% | +6.70% | +14.42% | +56.67% | 33.45B | |
| +1.41% | -4.77% | +29.30% | -0.54% | 23.7B | |
| -0.60% | +5.40% | +36.07% | +27.21% | 23.76B | |
| Average | -0.97% | +0.95% | +61.66% | +124.36% | 38.31B | |
| Weighted average by Cap. | -1.29% | +0.88% | +47.77% | +122.32% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 329K 439K 392K 362K 617K 41.62M 626K 4.36M 1.72M 21.81M 1.65M 1.61M 69.09M | 760K 1.02M 907K 837K 1.43M 96.28M 1.45M 10.08M 3.97M 50.44M 3.82M 3.73M 160M |
| Net income | -42.57M -56.9M -50.79M -46.86M -79.87M -5.39B -81.09M -565M -222M -2.82B -214M -209M -8.95B | -64.86M -86.69M -77.38M -71.39M -122M -8.21B -124M -860M -339M -4.3B -325M -318M -13.63B |
| Net Debt | -134M -180M -160M -148M -252M -17.01B -256M -1.78B -702M -8.91B -674M -660M -28.24B | -176M -235M -210M -193M -330M -22.26B -335M -2.33B -918M -11.66B -882M -863M -36.94B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-22 | US$19.66 | -0.05% | 3,078,639 |
| 26-10-21 | US$19.67 | +0.31% | 2,801,618 |
| 26-10-20 | US$19.61 | +0.15% | 13,962,894 |
| 26-10-19 | US$19.58 | +125.58% | 71,918,759 |
| 26-10-16 | US$8.680 | -7.17% | 1,131,128 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SLN Stock
Select your edition
All financial news and data tailored to specific country editions
